ISSN: 2577-4360
Authors: Manish A* and Badola A
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder which is characterized by an immature myeloid precursor cell proliferation and bone marrow failure. Acute leukemias comprise few most common malignant disorders. Due to effects of inherited genetic variations and disorders, pre-existing diseases, infectious agents, hobbies, occupations, prior treatments, and other factors have been identified, but not even a single is applicable to all cases. Despite robust advances in the fields of new drug targets and increased understanding of the biology, AML treatment remains same for decades with the majority relapse and dying due to the disease. Allogenic Bone Marrow Tissue transplant remains a best chance for cure for patients with intermediate or high risk disease. Advances in technologies like genomic profiling, including genome-wide gene expression, DNA copy number and single nucleotide polymorphism (SNP) genotype, spread some light on the role of genetics in these disparities. Combination of genetics and infection factors resulting in leukemogenesis. The exact nature, timing, sequence of the events and mechanisms leading to development of leukemia requires further investigations. This review summarizes the genetic studies that have improved outcome prediction and spread some light on the developing novel therapies.
Keywords: Leukemogenesis; Acute Myeloid Leukemia; Single Nucleotide Polymorphism
